Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog

Anti-Cancer Drugs

Volumn 21, Issue 6, 2010, Pages 609-618

  Berkovich, Liron ^a   Ben Shabat, Shimon ^a   Sintov, Amnon C ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Apoptosis; Calcipotrioene; Caspase; Vitamin D receptor; Vitamin D3

Indexed keywords

ANDROGEN; CALCIPOTRIOL; CALCITRIOL; CALCIUM; CASPASE 3; COLECALCIFEROL DERIVATIVE; CYTOCHROME C; O (2 HYDROXY 3 PIPERIDINOPROPYL)NICOTINIC AMIDOXIME; PROCASPASE 3; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRAIN MCF 7; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERCALCIURIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77953535850     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328337f3e9     Document Type: Article

References (49)

1. Walters MR. Newly identified actions of the vitamin D endocrine system. Endoc Rev 1992; 13:719-764.
2. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277:F157-F175.
3. Schneider DL. Management of osteoporosis in geriatric populations. Curr Osteoporos Rep 2008; 6:100-107.
4. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7:684-700.
5. Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 2004; 3:373-381.
6. Hsu J-Y, Feldman D, Mcneal JE, Peehl DM. Reduced 1a-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001; 61:2852-2856.
7. Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996; 56:264-267.
8. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25- dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998; 139:1197-1207.
9. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1alpha,25- dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002; 1:667-677.
10. Hansen CM, Frandsen TL, Brü nner N, Binderup L. 1 alpha,25- Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994; 12:195-202.
11. Young MR, Ihm J, Lozano Y,Wright MA, Prechel MM. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 1995; 41:37-45.
12. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1 alpha,25- Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997; 6:727-732.
13. Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004; 89-90:519-526.
14. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88:582S-586S.
15. James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996; 58:395-401.
16. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999; 8:241-248.
17. Carlberg C. Ligand-mediated conformational changes of the VDR are required for gene transactivation. J Steroid Biochem Mol Biol 2004; 89-90:227-232.
18. Wietrzyk J, Chodyń ski M, Fitak H,Wojdat E, Kutner A, Opolski A. Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs 2007; 18:447-457.
19. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 1988; 67:607-613.
20. Hussain-Hakimjee EA, Mehta RG. Regulation of steroid receptor expression by 1alpha-hydroxyvitamin D3 in hormone-responsive breast cancer cells. Anticancer Res 2009; 29:3555-3561.
21. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992; 267:20082-20086.
22. Reichrath J, Mü ller SM, Kerber A, Baum HP, Bahmer FA. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36:19-28.
23. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, et al. Role of Vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 2009; 69:967-975.
24. Van de Kerkhof PC. An update on vitamin D3 analogues in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998; 11:2-10.
25. Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician 2006; 73:636-644.
26. Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues tacalcitol calcipotriol and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003; 31:21-28.
27. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988; 37:889-895.
28. Guillemette C, Hum DW, Bé langer A. Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 1996; 57:225-231. (Pubitemid 26168901)
29. Reddel RR, Murphy LC, Sutherland RL. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res 1983; 43:4618-4624.
30. Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 1983; 43:3998-4006.
31. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16:200-257.
32. Norman AW, Zhou JY, Henry HL, Uskokovic MR, Koeffler HP. Structure- function studies on analogues of 1a,25-dihydroxyvitamin D3: differential effects on leukemic cell growth differentiation and intestinal calcium absorption. Cancer Res 1990; 50:6857-6864.
33. Posner GH, Suh BC, Petersen KS, Dolan P, Agoston ES, Kensler TW, et al. Difluoromethyl analogs of the natural hormone 1a,25-dihydroxyvitamin D3: design synthesis and preliminary biological evaluation. J Steroid Biochem Mol Biol 2007; 103:213-221.
34. Peleg S, Petersen KS, Suh BC,Dolan P, Agoston ES, Kensler TW, PosnerGH. Low-calcemic highly antiproliferative 1-difluoromethyl hybrid analogs of the natural hormone 1a,25-dihydroxyvitamin D3: design synthesis and preliminary biological evaluation. J Med Chem 2006; 49:7513-7517.
35. Hisatake J-I, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP. 56-trans-16-ene-Vitamin D3: a new class of potent inhibitors of proliferation of prostate breast and myeloid leukemic cells. Cancer Res 1999; 59: 4023-4029.
36. Grzywacz P, Plum LA, Sicinski RR, Clagett-Dame M, Deluca HF. Methyl substitution of the 25-hydroxy group on 2-methylene-19-nor-1a,25- dihydroxyvitamin D3 (2MD) reduces potency but allows bone selectivity. Arch Biochem Biophys 2007; 460:274-284.
37. Ohno A, Shimizu M, Yamada S. Fluorinated vitamin D analogs to probe the conformation of vitamin D in its receptor complex: 19F-NMR studies and biological activity. Chem Pharm Bull 2002; 50:475-483.
38. Usera AR, Dolan PM, Kensler TW, Posner GH. Antiproliferative low-calcemic fluorinated sulfone analogs of 1a,25-dihydroxyvitamin D3: chemical synthesis and biological evaluation. Bioorg Med Chem 2007; 15:5509-5518.
39. Posner GH, Kim HJ, Kahraman M, Jeon HB, Suh BC, Li H, et al. Highly antiproliferative low-calcemic side-chain ketone analogs of the hormone 1a,25-dihydroxyvitamin D3. Bioorg Med Chem 2005; 13:5569-5580.
40. Posner GH, Halford BA, Peleg S, Dolan P, Kensler TW. Conceptually new low-calcemic oxime analogues of the hormone 1a,25-dihydroxyvitamin D3: synthesis and biological testing. J Med Chem 2002; 45:1723-1730.
41. Posner GH, Jeon HB, Sarjeant A, Riccio ES, Doppalapudi RS, Kapetanovic IM, et al. Low-calcemic efficacious 1a,25-dihydroxyvitamin D3 analog QW- 1624F2-2: calcemic dose-response determination preclinical genotoxicity testing and revision of A-ring stereochemistry. Steroids 2004; 69:757-762.
42. Inaba M, Okuno S, Nishizawa Y, Imanishi Y, Katsumata T, Sugata I, Morii H. Effect of substituting fluorine for hydrogen at C-26 and C-27 on the side chain of 1,25-dihydroxyvitamin D3. Biochem Pharmacol 1993; 45:2331-2336.
43. Creagh EM, Conroy H, Martin SJ. Caspase-activation pathways in apoptosis and immunity. Immunol Rev 2003; 193:10-21.
44. Jänicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273:9357-9360.
45. Jänicke RU. MCF-MC7 breast cancer cells do not express caspase-3. Breast Cancer Res Treat 2009; 117:219-221.
46. Kuida K. Caspase-9. Int J Biochem Cell Biol 2000; 32:121-124.
47. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid a Bcl2 interacting protein mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94:481-490.
48. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther 2003; 2:573-580.
49. Sun SY, Hail N, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004; 96:662-672.